Loyal for Dogs (Loyal / Cellular Longevity) is redefining the paradigm of aging in dogs.

NAD+ supplements currently on the market claim to "slow the effects of aging," and to "support health as [dogs] age," but they do not promise to extend lifespan. Nor are they FDA-approved.

Loyal emphasizes that aging is the primary modifiable risk factor for most degenerative and chronic diseases in dogs. Their mission? To target the aging process itself, opening doors to healthier, longer lives for dogs.

At WVC 2024, I had the chance to chat with Dr. Brennen McKenzie, Loyal's Head of Veterinary Education, and he recently joined me on Petworking to continue the discussion.

We talked about the 3 pioneering drugs targeting critical molecular pathways associated with aging that Loyal has in the pipeline.

These include: - LOY-002 for senior dogs (10+ years old), focusing on metabolic health to extend lifespan.- LOY-001 & LOY-003 for larger dogs (40+ lbs), targeting hormonal overexpression of IGF-1, which Loyal has linked to the shorter lifespans experienced by large dogs.

Loyal is seeking FDA approval for all of these products, and by 2025, Loyal might be able to market LOY-001 under conditional approval, as the FDA has already granted "reasonable expectation of effectiveness."

That means by next year, there is a significant chance that if you are a large dog owner, your veterinarian could prescribe a product that can actually extend your dog's life.